TECENTRIQ is now approved in Europe for two indications

TECENTRIQ is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving TECENTRIQ.
TECENTRIQ is indicated for the tratement of adult patients with locally advanced or metastatic urothelial cancer (UC) after prior chemotherapy or who are considered cisplatin ineligible.

TECENTRIQ is the first anti-PDL1 cancer immunotherapy approved in NSCLC and mUC.

OAK: the largest Phase III cancer immunotherapy study in locally advanced or 
metastatic NSCLC patients previously treated with chemotherapy, regardless of 
PD-L1 expression1,2

IMvigor210: a Phase II, 2 cohort, multicentre international single-arm trial in locally advanced or metastatic urothelial carcinoma1,4

IMvigor211: randomised Phase III trial in locally advanced or metastatic UC patients previously treated with chemotherapy1*

* IMvigor211 did not meet the pre-specified primary endpoint for overall survival

Learn More

TECENTRIQ delivers proven survival1–2 and reports a favourable safety profile with low toxicity.

  • Low incidence of ≥grade 3 treatment-related AEs across UC and 
    NSCLC studies (N=2160)3
  • Low incidence of immune-related AEs across UC and NSCLC studies 
    (N=2160)3
  • <1% of patients discontinued treatment due to an immune-related AE

Read More

 Simple and convenient q3w fixed dosing for your patients and practice1

PD-L1 testing is not required to prescribe TECENTRIQ
Click For More Details

REFERENCES

1. TECENTRIQ Summary of Product Characteristics. Roche. September 2017.
 
2. Rittmeyer A, Barlesi F, Waterkamp D, et al; OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255-265.
 
3. TECENTRIQ Core Data Sheet. Version 2.0. Roche. September 2017.
 
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.